Mendling, W., Brasch, J., Cornely, O.A., Effendy, I., Friese, K., Ginter-Hanselmayer, G., Hof, H., Mayser, P., Mylonas, I., Ruhnke, M., Schaller, M. and Weissenbacher, E.R. (2015) Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneouscandidosis). Mycoses, 58, 1-15.
https://doi.org/10.1111/myc.12292

has been cited by the following article:

• TITLE: Polyhexamethylene Biguanide in Vaginal Solution Is Effective in the Treatment of Vulvovaginal Candidiasis: A Pilot Study

  AUTHORS: Alberto Biamonti, Angela Saracino

  KEYWORDS: Polyhexamethylene Biguanide, Vulvovaginal Candidiasis, Candida albicans Infection, Biguanide, Antiseptic

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.7 No.1, December 23, 2016

  ABSTRACT: Vaginitis is one of the most recurrent conditions that afflict women and require medical care. Vulvovaginal candidiasis (VVC) is frequently related to vaginal carriage of Candida albicans, an opportunistic polymorphic fungus, which colonizes the human skin, the mucosa and the reproductive tract. Actually, standard treatments to counteract vaginitis include several topical and oral treatments. The aim of this study was to evaluate the efficacy of a new biguanide compound, polyhexamethylene biguanide (PHMB) in avaginal solution, in women affected by vaginal candidiasis. For this reason, 40 women showing the symptoms previously ascribed to vaginal candidiasis were recruited and treated with a single PHMB dose of vaginal solution. After a single dose of treatment, 80% of them had a complete resolution of the fungal infection; furthermore, all of them reported clinical benefits, statistically significant reduction in both clinical signs and symptoms of candidiasis and a score’s reduction of 50%.